Multiple sclerosis and related disorders · 2026
Elevated serum complement shows promise as a potential clinically practical biomarker for disease activity in myelin oligodendrocyte glycoprotein antibody-associated disorders.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Huang Yiying, Wang Linling, Fabis-Pedrini Marzena, Luo Wenjing, Sun Wenxuan, Cheng Xi, Wang Jingqi, Lu Zhengqi, Hu Xueqiang, Qiu Wei, Kermode Allan G, Zhong Xiaonan
Аннотация
BACKGROUND: We aim to elucidate the differences in complement activation between myelin oligodendrocyte glycoprotein antibody-related disease (MOGAD) and neuromyelitis optic spectrum diseases (NMOSD), and explore the relationship between complement levels and disease activity in MOGAD.
METHODS: We retrospectively included 171 records of commonly used serum complement indicators, immunoglobulin, and systemic inflammatory markers from 96 MOGAD patients, 185 records from 97 anti - Aquaporins - 4 IgG (AQP4 - IgG) seropositive NMOSD cases, and 15 records from 11 AQP4 - IgG seronegative NMOSD cases.
RESULTS: MOGAD patients exhibited higher C3 (acute phase, p = 0.003) and C4 (acute phase, p < 0.001; whole course, p < 0.001) levels than NMOSD patients. In the MOGAD cohort, elevated CH50 levels were found in 76.47 % (130/170) cases, with higher frequencies during the acute phase 80.82 % (59/73). In the acute phase, MOGAD patients showed increased C4 (p = 0.022), CH50 (p = 0.021), and IgG (p = 0.031) levels. We also observed the dynamic fluctuations in complement concentrations after clinical attacks in MOGAD, with complement concentrations peaked during the acute phase and declined during remission (C3, 81.82 %, 9/11; C4, 63.64 %, 7/11; CH50, 72.73 %, 8/11). Positive correlations were observed between complement levels (p < 0.05) and IgG, CRP, ESR, and cerebrospinal fluid white blood cell count in MOGAD patients. Patients with higher CH50 levels tended to experience earlier recurrence than those with lower CH50 levels (log-rank p = 0.076).
CONCLUSIONS: Clinically practical complement indicators can reflect disease activity, and CH50 can serve as prognostic candidate biomarkers for relapse in MOGAD.
METHODS: We retrospectively included 171 records of commonly used serum complement indicators, immunoglobulin, and systemic inflammatory markers from 96 MOGAD patients, 185 records from 97 anti - Aquaporins - 4 IgG (AQP4 - IgG) seropositive NMOSD cases, and 15 records from 11 AQP4 - IgG seronegative NMOSD cases.
RESULTS: MOGAD patients exhibited higher C3 (acute phase, p = 0.003) and C4 (acute phase, p < 0.001; whole course, p < 0.001) levels than NMOSD patients. In the MOGAD cohort, elevated CH50 levels were found in 76.47 % (130/170) cases, with higher frequencies during the acute phase 80.82 % (59/73). In the acute phase, MOGAD patients showed increased C4 (p = 0.022), CH50 (p = 0.021), and IgG (p = 0.031) levels. We also observed the dynamic fluctuations in complement concentrations after clinical attacks in MOGAD, with complement concentrations peaked during the acute phase and declined during remission (C3, 81.82 %, 9/11; C4, 63.64 %, 7/11; CH50, 72.73 %, 8/11). Positive correlations were observed between complement levels (p < 0.05) and IgG, CRP, ESR, and cerebrospinal fluid white blood cell count in MOGAD patients. Patients with higher CH50 levels tended to experience earlier recurrence than those with lower CH50 levels (log-rank p = 0.076).
CONCLUSIONS: Clinically practical complement indicators can reflect disease activity, and CH50 can serve as prognostic candidate biomarkers for relapse in MOGAD.